Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001327

Atorvastatin calcium trihydrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Atorvastatin hemicalcium salt sesquihydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C66H68CaF2N4O10 · 3H2O
Numéro CAS:
344423-98-9
Poids moléculaire :
1209.39
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

atorvastatin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

Clé InChI

SHZPNDRIDUBNMH-NIJVSVLQSA-L

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Atorvastatin calcium trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1044516

Atorvastatin Calcium, United States Pharmacopeia (USP) Reference Standard

1044527

Atorvastatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044538

Atorvastatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044549

Atorvastatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044550

Atorvastatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1044571

Atorvastatin Related Compound E, United States Pharmacopeia (USP) Reference Standard

Y0001329

Atorvastatin impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001332

Atorvastatin impurity E, European Pharmacopoeia (EP) Reference Standard

1044593

Atorvastatin Related Compound I, United States Pharmacopeia (USP) Reference Standard

1044582

Atorvastatin Related Compound H, United States Pharmacopeia (USP) Reference Standard

PHR1873

Atorvastatin Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1869

Atorvastatin Related Compound B, pharmaceutical secondary standard, certified reference material

PHR1872

Atorvastatin Related Compound E, pharmaceutical secondary standard, certified reference material

PHR1874

Atorvastatin Related Compound I, pharmaceutical secondary standard, certified reference material

PHR1870

Atorvastatin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1871

Atorvastatin Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1868

Atorvastatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2421

1,1-Dimethylethyl (4R-cis)-6-Aminoethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Y0002315

Atorvastatin calcium, CRS, European Pharmacopoeia (EP) Reference Standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H351,H360D

Classification des risques

Carc. 2 - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Atorvastatin Related Compound B United States Pharmacopeia (USP) Reference Standard

USP

1044538

Atorvastatin Related Compound B

Atorvastatin Related Compound A United States Pharmacopeia (USP) Reference Standard

USP

1044527

Atorvastatin Related Compound A

Ezetimibe United States Pharmacopeia (USP) Reference Standard

USP

1269028

Ezetimibe

Hongshi Li et al.
Cardiovascular journal of Africa, 30(5), 268-274 (2019-07-31)
Our previous experiments showed that the transient sodium current (INa) was abnormally increased in early ischaemia and atorvastatin could inhibit INa. The aim of this study was to observe the time-dependent effects of simulated ischaemia on INa and characterise the
Fang Hu et al.
AMB Express, 9(1), 37-37 (2019-03-20)
The aim of the present study was to evaluate the protective effects of combined atorvastatin and amygdalin in a rat model of endometriosis. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in the peritoneal fluid were
Hui-Hui Li et al.
Acta pharmacologica Sinica, 41(3), 327-335 (2019-07-31)
23,24-Dihydrocucurbitacin B (designated as C95 in this article) is a cucurbitane triterpenoid that has been shown to possess a variety of pharmacological activities, such as anti-inflammatory and anti-HIV-1 activities etc. In this study, we investigated the effects of 23,24-dihydrocucurbitacin B
Masaki Watanabe et al.
Drug metabolism and pharmacokinetics, 30(2), 198-204 (2015-05-21)
Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statins are useful probes for OATP-mediated DDI, endogenous probes would be more practical for predicting
Alexander Treiber et al.
The Journal of pharmacology and experimental therapeutics, 350(1), 130-143 (2014-04-29)
Treatment of pulmonary arterial hypertension with the endothelin receptor antagonist bosentan has been associated with transient increases in liver transaminases. Mechanistically, bosentan inhibits the bile salt export pump (BSEP) leading to an intrahepatic accumulation of cytotoxic bile salts, which eventually

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique